Top

Published in:

01-07-2018 | Original Scientific Report

A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma

Authors: Shuai Wang, Ke Ma, Zongwei Chen, Xiaodong Yang, Fenghao Sun, Yulin Jin, Yu Shi, Wei Jiang, Qun Wang, Cheng Zhan

Published in: World Journal of Surgery | Issue 7/2018

Abstract

Background

Malignant pleural mesothelioma (MPM) is a rare malignancy with heterogeneous outcomes. This study was aimed to develop a nomogram to precisely and visually predict survival of MPM patients.

Methods

Data from Surveillance, Epidemiology, and End Results database (1973–2014) on MPM were screened and retrieved. The prognostic effects of variables, including age, sex, race, year of diagnosis, laterality, histology, tumor stage, surgery, chemotherapy, and radiotherapy were analyzed using Kaplan–Meier method and Cox proportional hazard model. A nomogram was formulated to predict overall survival of MPM patients.

Results

A total of 1092 cases who met inclusion criteria were included in this study. The overall 1-, 2-, and 3-year survival rate in the entire cohort was 45.1, 23.0, and 12.1%, with median survival of 11 months. Cox regression analysis showed that age (P < 0.001), race (P = 0.003), histology type (P < 0.001), T stage (P < 0.001), M stage (P < 0.001), TNM stage (P < 0.001), cancer-directed surgery (P < 0.001), and chemotherapy (P < 0.001) were all independent prognostic factors of MPM patients. A nomogram was established based on the results of multivariate analysis. The internal bootstrap resampling approach suggested the nomogram had sufficient discriminatory power with the C-index of 0.705 (95% CI 0.681–0.729). The calibration plots also demonstrated good consistence between the prediction and the observation.

Conclusions

We developed a nomogram to accurately predict clinical outcomes of MPM patients based on individual characteristics. Risk stratification by the survival nomogram could optimize individual therapies and follow-up.

Available only for authorised users

Baumann F, Ambrosi JP, Carbone M (2013) Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol 14:576–578CrossRefPubMed

Milano MT, Zhang H (2010) Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 5:1841–1848CrossRefPubMed

Burt BM, Bader A, Winter D et al (2012) Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin Cancer Res 18:1568–1577CrossRefPubMed

Kadota K, Kachala SS, Nitadori J et al (2012) High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology. J Thorac Oncol 7:1192–1197CrossRefPubMedPubMedCentral

Rusch VW, Giroux D, Kennedy C et al (2012) Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 7:1631–1639CrossRefPubMed

Ettinger DS, Wood DE, Akerley W et al (2016) NCCN guidelines insights: malignant pleural mesothelioma, Version 3.2016. J Natl Compr Canc Netw 14:825–836CrossRefPubMed

Rusch VW, Chansky K, Kindler HL et al (2016) The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J Thorac Oncol 11:2112–2119CrossRefPubMed

Galateau-Salle F, Churg A, Roggli V et al (2015) The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol 11:142–154CrossRef

Sun F, Ma K, Yang X et al (2017) A nomogram to predict prognosis after surgery in early stage non-small cell lung cancer in elderly patients. Int J Surg 42:11–16CrossRefPubMed

10.

International Union Against Cancer (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Oxford, pp 60–71

11.

Travis WD, Brambilla E, Burke AP et al (2015) Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 10:1240–1242CrossRefPubMed

12.

Heller G, Mo Q (2016) Estimating the concordance probability in a survival analysis with a discrete number of risk groups. Lifetime Data Anal 22:263–279CrossRefPubMed

13.

Meyerhoff RR, Yang CF, Speicher PJ et al (2015) Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 196:23–32CrossRefPubMedPubMedCentral

14.

Spirtas R, Connelly RR, Tucker MA (1988) Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 41:525–530CrossRefPubMed

15.

Taioli E, Wolf AS, Camacho-Rivera M et al (2014) Women with malignant pleural mesothelioma have a threefold better survival rate than men. Ann Thorac Surg 98:1020–1024CrossRefPubMed

16.

Husain AN, Colby T, Ordonez N et al (2013) Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 137:647–667CrossRefPubMed

17.

Stahel RA, Weder W, Felip E et al (2008) Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19:ii43–ii44PubMed

18.

Bovolato P, Casadio C, Billè A et al (2014) Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 9:390–396CrossRefPubMed

19.

Helland Å, Solberg S, Brustugun OT (2012) Incidence and survival of malignant pleural mesothelioma in Norway: a population-based study of 1686 cases. J Thorac Oncol 7:1858–1861CrossRefPubMed

20.

Leuzzi G, Rea F, Spaggiari L et al (2015) Prognostic score of long-term survival after surgery for malignant pleural mesothelioma: a multicenter analysis. Ann Thorac Surg 100:890–897CrossRefPubMed

21.

Nakas A, Waller D (2014) Predictors of long-term survival following radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 46:380–385 (discussion 385) CrossRefPubMed

22.

van der Bij S, Koffijberg H, Burgers JA et al (2012) Prognosis and prognostic factors of patients with mesothelioma: a population-based study. Br J Cancer 107:161–164CrossRefPubMedPubMedCentral

23.

Flores RM, Routledge T, Seshan VE et al (2008) The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 136:605CrossRefPubMed

24.

Sugarbaker DJ, Richards WG, Bueno R (2014) Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 260:577CrossRefPubMedPubMedCentral

25.

Bolukbas S, Eberlein M, Kudelin N et al (2013) Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma. Eur J Cardio-Thoracic Surg 44:119CrossRef

26.

Leuzzi G, Rea F, Spaggiari L et al (2015) Prognostic score of long-term survival after surgery for malignant pleural mesothelioma: a multicenter analysis. Ann Thorac Surg 100:890–897CrossRefPubMed

27.

Kindler HL (2012) Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol 7:1623–1624CrossRefPubMed

28.

Hysi I, Le Pimpec-Barthes F, Alifano M et al (2014) Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study. Oncol Rep 31:415–421CrossRefPubMed

29.

Kadota K, Suzuki K, Sima CS et al (2011) Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 6:896–904CrossRefPubMed

30.

Kelly RJ, Sharon E, Hassan R (2011) Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73:256–263CrossRefPubMedPubMedCentral

31.

Rimner A, Zauderer MG, Gomez DR et al (2016) Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol 34:2761–2768CrossRefPubMedPubMedCentral

Title: A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma
Authors: Shuai Wang
Ke Ma
Zongwei Chen
Xiaodong Yang
Fenghao Sun
Yulin Jin
Yu Shi
Wei Jiang
Qun Wang
Cheng Zhan
Publication date: 01-07-2018
Publisher: Springer International Publishing
Published in: World Journal of Surgery / Issue 7/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-017-4424-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

Risk Factors for Mortality and Morbidity in Elderly Patients Presenting with Digestive Surgical Emergencies

The Use of a Pre-operative Carbohydrate Drink in Patients with Diabetes Mellitus: A Prospective, Non-inferiority, Cohort Study

Yonsei Experience of 5000 Gasless Transaxillary Robotic Thyroidectomies

The Surgical Strategy in Massive Corrosive Injury in Digestive Tract: Is the Extensive Surgery Appropriate?

Breast and Tumour Volume Measurements in Breast Cancer Patients Using 3-D Automated Breast Volume Scanner Images

Early Management of Retained Hemothorax in Blunt Head and Chest Trauma